|
Posted on 06/04/2021 2:37:32 PM PDT by ransomnote
Q is the result of the sacrifices and commitment of countless patriots to win back our captured country from the Deep State and achieve the transformation President Trump promised in this campaign video. President Trump has said the awakening of the public is key to this transformation.
Q describes this awakening as follows:
"The Great Awakening ('Freedom of Thought’), was designed and created not only as a backchannel to the public (away from the longstanding 'mind’ control of the corrupt & heavily biased media) to endure future events through transparency and regeneration of individual thought (breaking the chains of ‘group-think’), but, more importantly, aid in the construction of a vehicle (a ‘ship’) that provides the scattered (‘free thinkers’) with a ‘starter’ new social-networking platform which allows for freedom of thought, expression, and patriotism or national pride (the feeling of love, devotion and sense of attachment to a homeland and alliance with other citizens who share the same sentiment).When ‘non-dogmatic’ information becomes FREE & TRANSPARENT it becomes a threat to those who attempt to control the narrative and/or the stable.
When you are awake, you stand on the outside of the stable (‘group-think’ collective), and have ‘free thought’.
"Free thought" is a philosophical viewpoint which holds that positions regarding truth should be formed on the basis of logic, reason, and empiricism, rather than authority, tradition, revelation, or dogma.
When you are awake, you are able to clearly see.
The choice is yours, and yours alone.
Trust and put faith in yourself.
You are not alone and you are not in the minority.
Difficult truths will soon see the light of day.
WWG1WGA!!!" ~ Q (#3038)
The video, Qanon is 100% coming from the Trump Administration, is just one of many excellent responses to the all-important question, "Whom does Q serve?"
Q Boot Camp is a quick, condensed way to learn the background and basics about the Q movement.
Q has reminded us repeatedly that together, we are strong. As the false "narrative" is destroyed and the divisive machinery put in place by the Deep State fails, the fact that patriotism has no skin color or political party is exposed for all to see.
In the battle between those who strip us our constitutional rights, we can't afford to let false divisions separate us any longer. We, and our country, will be forever made stronger by diligently seeking the truth, independence and freedom of thought.
Where We Go 1, We Go All
Monoclonal antibody can change Covid scenario: Gangaram Hospital
New Delhi — At a time when the country is passing through the second wave of Covid-19, Delhi-based Sir Gangaram Hospital claims that monoclonal antibody can be a game changer with its better hold on the deadly pandemic.
As per the hospital, the monoclonal antibodies will change the scenario of Covid-19 pandemic very soon.
The healthcare facility came with new findings after treatment of two patients recently at its centre by successfully using monoclonal antibody which showed fast progression of symptoms within first seven days and changed the outcome.
A 36-year-old healthcare worker with high grade fever, cough, myalgia, severe weakness and leucopenia was administered REGCov2 (CASIRIVIMAB Plus IMDEVIMAB) on day six of disease, the hospital said in a statement.
“Patient’s parameter improved within 12 hours and was discharged,” said the hospital.
The second case was of R.K. Razdan, an 80-year-old male diabetic and hypertensive patient, who was presented with high grade fever, cough and toxic look.
Razdan’s oxygen saturation was more than 95 per cent on room air. “CT Scan confirmed mild disease. He was given REGCov2 on Day 5 of disease. Patient’s parameter improved with next 12 hours.”
According to Pooja Khosla, Senior Consultant, Department of Medicine, Sir Ganga Ram Hospital, “Monoclonal antibody could prove to be a game changer in times to come if used at appropriate time.”
“It can avoid hospitalization in high-risk group and progression to severe disease. It can help escaping or reducing the usage of steroids and immunomodulation which would further reduce the risk of fatal infections like Mucormycosis, secondary bacterial and viral infections like CMV.”
Khosla said this awareness about early identification of high-risk category in our population and timely therapy with monoclonal antibody as day care treatment may reduce the burden of cost on healthcare sector.
https://freerepublic.com/focus/f-news/3966405/posts
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses, like SARS-CoV-2. Like other infectious organisms, SARS-CoV-2 can mutate over time, resulting in genetic variation in the population of circulating viral strains.
So we already friggin know this works? WTF is wrong with Fauci????
He is Gates’s friend and they want to depopulate Planet Earth.
***Mt. McLaughlin? (sp?)
~~~~~~~~~~~~~~~~~~~~~
Mt. Hood, I’m thinking.
32 times, and he does not care.
That’s how mine work. I dial up a 250 pound dose, squirt it in a syringe, and take half. The link I posted has a video that shows how to accurately measure small doses too.
.
I go by the notches also.
marking to show a pilot buddy
thanx
Sadly, yes.
mark
.
Good thanx, is that a 18mg dose and how often?
.
Good thanx, is that a 18mg dose and how often?
..
No, it was just a stupid responce by my about Marley and his GANJA
Are you making fun of how people look, BR?
I am so telling on you.
You are right, I just checked.
I am not bald. I just wear my hair very short.
While I’m here...
(We don’t get enough sunshine here in the Tongass to sit around inside when it stops raining)...
This one goes out to Ruby and Wandrea:
https://youtu.be/wBjPAqmnvGA
What state is that, Arizona?
Thanks.
https://freerepublic.com/focus/f-news/3966460/posts
10 Serious COVID Patients Given Israeli Drug, Leave Hospital in One Day
Jerusalem Post ^ | MAY 29, 2021 | MAAYAN JAFFE-HOFFMAN
Posted on 6/9/2021, 12:48:49 PM by nickcarraway
The data showed a 40% decrease in lung inflammation from treatment – from 55% to 15%, as seen in chest X-rays * Rambam Health Care Campus doctor: ‘Results extremely impressive’
An Israeli biotechnology company has claimed a 100% success rate in the first 10 patients treated with its drug as part of an early-stage clinical trial at Rambam Health Care Campus in Haifa.
The company, Bonus BioGroup, presented the preliminary findings of its Phase I/II trial to peers at the International Society for Cell & Gene Therapy conference in New Orleans last week and shared the results in a statement released to the Tel Aviv Stock Exchange.
The Jerusalem Post, which first wrote about the treatment in May 2020, reviewed the PowerPoint presented at the conference and the five-page letter sent to the exchange. The company’s CEO and director, Dr. Shai Meretzki, told the Post that the team is now working on publishing its results in a peer-reviewed journal.
Bonus’s MesenCure, which consists of activated Mesenchymal Stromal Cells (MSCs) that are isolated from the adipose tissue of healthy donors, was found to reduce inflammation and alleviate respiratory and other symptoms in patients suffering from life-threatening respiratory distress brought on by COVID-19.
“So far, the results of the treatment with the drug MesenCure are extremely impressive and an improvement over the results of other treatments,” said Dr. Shadi Hamoud, principal investigator in the clinical trial and deputy director of the Department of Internal Medicine E at Rambam.
He said the results were so promising that the hospital was already examining use of the treatment for other indications.
Bonus reported on 10 COVID patients between the ages of 45 to 75, all with severe symptoms. Ninety percent of them also had comorbidities.
The data showed a 40% decrease in lung inflammation from treatment – from 55% to 15%, as seen in chest X-rays, in the first five days after treatment. One month later, lung inflammation reached 1%.
Additionally, patients showed significantly improved respiratory function, with blood oxygen saturation increasing to 95% and lung functioning returning to almost entirely normal levels after only one month.
Meretzki shared a laboratory image of a healthy lung, a sick lung and lung treated with MesenCure. “The treated lung looks almost identical to the normal, healthy lung – complete healing, complete prevention of damage to the lung,” Meretzki said.
Most strikingly, patients were discharged from the hospital after a median duration of only one day following the treatment.
And there were no adverse effects associated with MesenCure, the company reported.
Meretzki said the trial followed patients for 30 days post administration of the treatment. All but one had survived. The patient who died did not pass away from COVID-19 but a severe preexisting condition.
Many COVID-19 patients die because of an increase in the production of inflammatory molecules called cytokine, rather than the virus itself, Meretzki explained. When the immune system secretes too many cytokines, a so-called “cytokine storm” can erupt. Such an excessive immune response ravages healthy lung tissue, leading to acute respiratory distress syndrome or failure, and eventually death.
Bonus was founded in 2008. It has been working with MSCs for a decade from its Haifa headquarters, where it developed its core product, a tissue-engineered bone graft that is also based on MSCs.
Meretzki said that MSCs are cells that are “found in every one of us; they are responsible for damage control and a variety of day-to-day activities.”
When the coronavirus outbreak started in early 2020, Bonus started investigating the potential of MSCs to possibly reduce the cytokine storm in COVID-19 patients.
The Phase II trial is slated to continue at Rambam and include another 50 patients. However, because of the low-level of infection in Israel, Bonus has applied for approval to carry out the trial in Europe as well, Meretzki said.
He told the Post that the Phase II trial should be completed quickly once the remaining patients are fully enrolled.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.
